ArticleJournal of thoracic disease2026
Temporal trends in dual bronchodilator prescribing before and after GOLD 2023 publication.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) exacerbations are a leading cause of hospitalization and readmission. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 report recommends dual long-acting bronchodilator (LABD) therapy consisting of combined long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapy following hospitalization for COPD exacerbation. We evaluated temporal trends in dual LABD prescribing before and after publication of the GOLD 2023 recommendations. Methods: We performed a retrospective cohort study of 2,537 patients hospitalized with COPD exacerbation at Henry Ford Hospital between December 2017 and July 2024. Patients were categorized into pre-guideline (December 2017-April 2023) and post-guideline (May 2023-July 2024) periods. The primary outcome was the discharge prescribing of dual LABD therapy. Results: Discharge prescribing of dual LABD therapy was higher in the post-guideline period compared with the pre-guideline period (56.3% Conclusions: Discharge prescribing of dual LABD therapy increased over the study period and remained higher following publication of the GOLD 2023 recommendations. Temporal trend analysis suggested that prescribing patterns were already evolving prior to formal guideline publication, likely reflecting increasing incorporation of emerging evidence into clinical practice. Further studies are needed to evaluate longer-term prescribing trends and associated clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.